luliconazole

luliconazole

(loo-li-kon-a-zole) ,

Luzu

(trade name)

Classification

Therapeutic: antifungals
Pharmacologic: azoles
Pregnancy Category: C

Indications

Topical treatment of interdigital tinea pedis, tinea cruris and tinea corporis.

Action

Inhibits an enzyme necessary for ergosterol synthesis, required for fungal cell membranes.
Antifungal action.

Therapeutic effects

Resolution of dermal fungal infection.
Active against Trichyphyton rubrum and Epidermpophyton floccosum.

Pharmacokinetics

Absorption: Small amounts are systemically absorbed.
Distribution: Unknown.
Protein Binding: >99%
Metabolism and Excretion: Unknown.
Half-life: unk

Time/action profile (improvement/resolution of infection)

ROUTEONSETPEAKDURATION
topunk3–4 wk†unknown
†Following initiation of treatment.

Contraindications/Precautions

Contraindicated in: None noted;
Use Cautiously in: Obstetric: Use in pregnancy only if potential benefit justifies any fetal risks; Lactation: Use cautiously in breast feeding women. Pediatric: Safe and effective use in children <18 yr not established.

Adverse Reactions/Side Effects

Dermatologic

  • application site reactions

Interactions

Drug-Drug interaction

May inhibit the activity of the CYP3A4 and CYP2C19 enzymes.

Route/Dosage

Topical (Adults) Interdigital tinea pedisApply to affected and surrounding areas once daily for two weeks; Tinea cruris and tinea corporisApply to affected and surrounding areas once daily for one week.

Availability

Topical cream: 1%

Nursing implications

Nursing assessment

  • Inspect involved areas of skin and mucous membranes before and frequently during therapy. Increased skin irritation may indicate need to discontinue medication.

Potential Nursing Diagnoses

Risk for impaired skin integrity (Indications)
Risk for infection (Indications)

Implementation

  • Consult health care professional for proper cleansing technique before applying medication.
  • Topical: For Interdigital tinea pedis: Apply thin layer to cover affected area and approximately 1 inch of immediate surrounding area completely daily for 2 wk.
    • For Tinea Cruris or Tinea Corporis: Apply thin layer to affected area and approximately 1 inch of immediate surrounding area daily for 1 wk.
    • Avoid the use of occlusive wrappings or dressings unless directed by health care professional. Wash hands after application.

Patient/Family Teaching

  • Instruct patient to apply medication as directed for full course of therapy, even if feeling better. Emphasize the importance of avoiding the eyes and vagina.
  • Patients with athlete’s foot should be taught to wear well-fitting, ventilated shoes, to wash affected areas thoroughly, and to change shoes and socks at least once a day.
  • Advise patient to report increased skin irritation or lack of response to therapy to health care professional.
  • Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and consult health care professional before taking any new medications.
  • Advise female patient to notify health care professional if pregnancy is planned or suspected or if breastfeeding.

Evaluation/Desired Outcomes

  • Decrease in skin irritation and resolution of infection.
References in periodicals archive ?
Tenders are invited for Cream Luliconazole 1 Percent Tube Of 10 Gm - 20 Gm
A 1% topical luliconazole cream yielded complete clearance in more than 20% of patients with tinea cruris and patients with tinea pedis, compared with less than 10% of placebo patients in a pair of randomized, multicenter double-blind studies.
Luliconazole has been approved in Japan since 2005.
a privately-held biotechnology company, today announced that it has entered into a sublicense and purchase option agreement with an undisclosed partner to develop luliconazole exclusively for tinea infections of the skin in the Americas and Europe.
The company expects to initiate a Phase 1/2a trial of luliconazole in the U.
Luliconazole is one of the most potent and broad-spectrum topical antifungal agents in development and will be advancing to Phase 3 clinical development in the U.
Vontz will provide an overview of TOPICA and its clinical development plans for luliconazole, one of the most potent and broad spectrum topical antifungal agents, for the treatment of onychomycosis (fungal infections of the nail) and tinea pedis (athlete's foot).
The company is poised for success with its experienced board, management team, significant market potential and novel molecule, luliconazole.
April 22 /PRNewswire/ -- TOPICA Pharmaceuticals today announced the enrollment of patients in a Phase 2 clinical trial evaluating luliconazole for the treatment of tinea pedis (athlete's foot).
Luliconazole is an azole drug, meaning it is broad spectrum and kills dermatophytes, yeast, and molds.
Luliconazole (Luzu), an azole anti-fungal, is a cream used for the treatment of tinea pedis, tinea cruris, and tinea corporis.